Earli
- Company typePrivate
- Founded2018
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Earli firmographics
Firmographics- Name
- Earli
- Legal name
- Earli Inc.
- Website
- https://earli.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Earli industry classification
Industry- Product category
- Cancer Diagnostics & Therapeutics Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
Keywords
Where Earli is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Earli business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Pre-revenue Stage: Earli is a clinical-stage biotechnology company with no commercialized products. The company is focused on developing its Synthetic Biopsy platform through clinical trials. Revenue will be generated through potential pharmaceutical partnerships, licensing agreements, and eventual diagnostic/therapeutic product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Earli product offering
Product offeringCore offering
Earli develops the Synthetic Biopsy platform, which uses AI-designed cancer-activated genetic switches delivered via lipid nanoparticles to program cancer cells to produce synthetic biomarkers. These synthetic biomarkers are detectable through standard imaging (PET scans) or bodily fluid analysis, enabling non-invasive early cancer detection, tumor localization, and in vivo drug production applications for precision cancer therapy. The platform combines a proprietary AI prediction model ("Oracle") with high-throughput wet lab testing.
Product overview
Earli offers a unified platform approach centered on its Synthetic Biopsy technology, which uses AI to design genetic switches that activate exclusively in cancer cells. The core Cancer-Activated Gene Expression Platform serves as the foundation, with Diagnostic Imaging Application and In Vivo Drug Production Application built on top. This integrated approach enables both cancer detection (forcing cancer cells to produce detectable synthetic biomarkers) and therapeutic applications (programming cancer cells to produce their own immune therapies).
Differentiator
Problem solved
Functional benefit
Products and services
- Synthetic Biopsy
Quantifiable outcome
- Up to 250,000 genetic switches per batch tested, enabling broad biomarker coverage.
Companies that use Earli
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Earli technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Earli partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- NanobiotixcoreStrategic collaboration for generating preclinical data, combining Nanobiotix's nanotechnology with Earli's synthetic biology platform.
- UC Davis - Center for Companion Animal HealthcoreClinical trial partnership for conducting veterinary studies using Earli's cancer detection technology in companion animals.
- Olivia Newton-John Cancer Centre (Australia)coreAustralian clinical trial site for Earli's human cancer detection studies.
- Chris O'Brien Lifehouse (Australia)coreAustralian clinical trial site participating in Earli's cancer detection trials.
- ICON Cancer Centre (Australia)coreAustralian oncology center conducting clinical trials with Earli's technology.
- PASO (Australia)coreAustralian clinical trial site participating in Earli's cancer detection research.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Earli competitors and assessment
Company assessmentDirect peers
- GRAIL: GRAIL develops the Galleri multi-cancer early detection blood test, making it the most direct competitor to Earli's Synthetic Biopsy. Both companies pursue blood-based detection of multiple cancer types at early stages, targeting the same healthcare provider and oncology customer base.
- Guardant Health: Guardant Health is a leading liquid biopsy company offering oncology blood tests for treatment selection, monitoring, and most recently early detection (Shield, Reveal). It directly competes with Earli in non-invasive cancer detection and shares the same target customer base of oncologists and healthcare providers.
- Exact Sciences: Exact Sciences commercializes Cologuard for colorectal cancer screening and Oncotype DX for cancer treatment decisions, and acquired Thrive Earlier Detection to expand into multi-cancer early detection. It is a direct competitor to Earli's early cancer detection value proposition.
- Natera: Natera's Signatera tumor-informed MRD test and early cancer detection efforts make it a direct peer. Both operate in the blood-based oncology detection space targeting similar oncologist and clinical trial customer segments.
- Personalis: Personalis offers ImmunoID Next and NeXT Personal liquid biopsy tests for tumor profiling and MRD detection. It competes with Earli in oncology liquid biopsy and shares the same pharmaceutical/biotech clinical trial customer base.
Emerging players
- Strand Therapeutics: Strand Therapeutics develops synthetic biology-based mRNA therapeutics programmed to express therapeutic payloads in specific cell types, including cancer. Both companies use synthetic biology/genetic switches for cancer treatment and overlap in gene-construct design and LNP delivery technologies.
- AbCellera: AbCellera is an AI/ML-enabled biologic drug discovery platform that combines computational antibody design with high-throughput wet lab testing — architecturally analogous to Earli's Oracle AI + 250,000-switch wet lab data flywheel. Both pursue AI-driven biological discovery.
- Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics, including for oncology. Both Generate and Earli apply AI-driven design to biologic discovery, share a similar high-throughput compute-plus-wet-lab architecture, and target cancer as a primary therapeutic area.
Broad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors and hematologic malignancies. As a broad incumbent in cancer molecular diagnostics, it overlaps with Earli's oncology detection ambitions, though Foundation is positioned as a tissue-based CGP leader rather than a synthetic biomarker / liquid biopsy player.
- BioNTech: BioNTech pioneered mRNA-based cancer therapeutics and is a broad incumbent in synthetic biology-driven oncology. Both BioNTech and Earli use nucleic-acid constructs delivered via lipid nanoparticles to program cells for cancer treatment, and BioNTech represents a credible potential acquirer or competitor for Earli's therapeutic platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Earli social profiles
Digital presenceEarli financial estimates
Financial estimateRevenue estimate
Valuation estimate
Earli leadership team
Management profileNumber of profiles
Profiles5 records
Earli subsidiaries and ownership
Company hierarchySubsidiaries1 record
Earli funding detail
Funding detailFunding overview
Funding rounds6 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Earli M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Earli
What does Earli do?
Earli develops the Synthetic Biopsy platform, which uses AI-designed cancer-activated genetic switches delivered via lipid nanoparticles to program cancer cells to produce synthetic biomarkers. These synthetic biomarkers are detectable through standard imaging (PET scans) or bodily fluid analysis, enabling non-invasive early cancer detection, tumor localization, and in vivo drug production applications for precision cancer therapy. The platform combines a proprietary AI prediction model ("Oracle") with high-throughput wet lab testing.
Is Earli a public or private company?
Earli is a private company. It is classified as venture growth investor backed and is currently operating.
When was Earli founded?
Earli was founded in 2018. It employs 11 to 50 people.
Where is Earli based?
Earli is headquartered in South San Francisco, United States, in the North America region.
How does Earli make money?
One revenue line is on record: pre-revenue Stage.
Who are Earli's main competitors?
Direct peers on record are GRAIL, Guardant Health, Exact Sciences, Natera and Personalis. Emerging players are Strand Therapeutics, AbCellera and Generate Biomedicines. Broad incumbents are Foundation Medicine and BioNTech.
Does Earli have an API?
No public API is recorded for Earli.
What industry is Earli in?
Earli's product category is Cancer Diagnostics & Therapeutics Biotechnology. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 541714 and its SIC code is 2835.